Ionis Pharmaceuticals (IONS) PT Lowered to $54 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IONS Hot Sheet
Price: $40.30 -0.3%
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Morgan Stanley analyst David Lebowitz lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $54.00 (from $56.00) while maintaining a Underweight rating.
You May Also Be Interested In
- Ionis to hold third quarter 2026 financial results webcast
- Viridian Therapeutic (VRDN) PT Raised to $43 at Stifel
- Datadog (DDOG) PT Lowered to $285 at Rosenblatt
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
